A Phase 3 Trial of DT120 for Generalized Anxiety Disorder (Voyage) (NCT06741228)
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, 12-Week Study (Part A) With a 40-Week Open-label Extension (Part B) Evaluating the Efficacy and Safety of Oral DT120 Compared to Placebo in the Treatment of Adults With Generalized Anxiety Disorder - Voyage
🩺 Plain-English Summary (8th-Grade Level)
A Phase 3 Double-blind, Placebo-controlled Study (Part A) with an Open-label Extension (Part B) Evaluating DT120 Compared to Placebo in Generalized Anxiety Disorder - Voyage
Who can join: Review the eligibility criteria below.
Location: Lighthouse Psychiatry — Gilbert, Arizona
Age range: 18 Years to 74 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (34 Sites)
Showing the first 25 of 34 sites.
- Lighthouse Psychiatry — Gilbert, Arizona
- Scottsdale Research Institute — Scottsdale, Arizona
- Kadima Neuropsychiatry Institute — La Jolla, California
- UCSF Department of Neurology — San Francisco, California
- Psychedelic Science Institute — Santa Monica, California
- Mountain View — Denver, Colorado
- Clinical Neuroscience Solutions Inc. — Jacksonville, Florida
- Segal Trials — Lauderhill, Florida
- Atlanta Center for Medical Research — Atlanta, Georgia
- iResearch Atlanta — Decatur, Georgia
- CenExel iResearch, LLC — Savannah, Georgia
- Uptown Research Institute — Chicago, Illinois
- Adams Clinical Boston — Boston, Massachusetts
- Adams Clinical Watertown — Watertown, Massachusetts
- Hassman Research Institute — Marlton, New Jersey
- Spectrum Neuroscience and Treatment Institute — New York, New York
- Adams Clinical Harlem — New York, New York
- New York State Psychiatric Institute (NYSPI) — New York, New York
- Adams Clinical Bronx — The Bronx, New York
- Cleveland Clinic Lutheran Hospital — Cleveland, Ohio
- Summit Headlands LLC — Portland, Oregon
- Scranton Medical Institute — Moosic, Pennsylvania
- Adams Clinical Philadelphia — Philadelphia, Pennsylvania
- Coastal Carolina Research Center — North Charleston, South Carolina
- Clinical Neuroscience Solutions, Inc. — Memphis, Tennessee
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Generalized Anxiety Disorder
- A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Panorama) — Little Rock, Arkansas
- MBSR Mechanisms in GAD — New York, New York
- Efficacy and Safety of Inhaled NC-107 As Compared to Placebo After 4 Weeks of Treatment in Patients with Anxiety — Carrollton, Texas
- Understanding of Participation Trends Within Generalized Anxiety Disorder Patients Involved in Clinical Trials — San Francisco, California
- Adjunctive Treatment With L-methylfolate for Treatment-Resistant Generalized Anxiety Disorder: a Pilot Study — Kingston, Ontario
Explore by condition: All Generalized Anxiety Disorder clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.